Trevi Therapeutics (TRVI) Return on Capital Employed (2019 - 2026)
Trevi Therapeutics (TRVI) posted quarterly Return on Capital Employed of 28.35% for Q1 2026, up 2044.0% year-over-year from 1.32% in Q1 2025, and down 10.13% quarter-over-quarter from 25.74% in Q4 2025.
Trevi Therapeutics (TRVI) Return on Capital Employed (2019 - 2026) Analysis & Trends
Trevi Therapeutics' Return on Capital Employed history runs 8 years deep, the most recent figure standing at 28.35% for Q1 2026.
- In Q1 2026, Return on Capital Employed rose 2044.0% year-over-year to 28.35%; the TTM figure through Mar 2026 stood at 28.35% (up 2044.0% YoY), while the FY2025 annual figure was 34.64%, up 2284.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 28.35%, down from 25.74% in the prior quarter.
- The five-year high for Return on Capital Employed was 25.7% in Q3 2025, with the low at 145.67% in Q1 2022.
- The 5-year median for Return on Capital Employed is 34.93% (2022), against an average of 48.74%.
- Peak annual rise in Return on Capital Employed reached 11892 bps in 2022, while the deepest fall reached 6514 bps in 2022.
- Trevi Therapeutics' Return on Capital Employed stood at 26.63% in 2022, then sank by 47 bps to 39.07% in 2023, then plunged by 66 bps to 64.9% in 2024, then jumped by 60 bps to 25.74% in 2025, then dropped by 10 bps to 28.35% in 2026.
- Business Quant data shows TRVI's Return on Capital Employed at 28.35% in Q1 2026, 25.74% in Q4 2025, and 25.7% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Trevi Therapeutics | 2.63 Bn | 2.63 Bn | - | -22.12% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -22.12% |
| Mar 31, 2026 | -28.35% |
| Dec 31, 2025 | -25.74% |
| Sep 30, 2025 | -25.70% |
| Jun 30, 2025 | -33.85% |
| Mar 31, 2025 | -48.79% |
| Dec 31, 2024 | -64.90% |
| Sep 30, 2024 | -77.47% |
| Jun 30, 2024 | -62.18% |
| Mar 31, 2024 | -48.62% |
| Dec 31, 2023 | -39.07% |
| Sep 30, 2023 | -33.93% |
| Jun 30, 2023 | -29.85% |
| Mar 31, 2023 | -28.61% |
| Dec 31, 2022 | -26.63% |
| Sep 30, 2022 | -34.93% |
| Jun 30, 2022 | -74.30% |
| Mar 31, 2022 | -145.67% |
| Dec 31, 2021 | -145.56% |
| Sep 30, 2021 | -131.17% |